Global S&T Development Trend Analysis Platform of Resources and Environment
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
A high tumour mutational burden (hypermutation) is observed in some gliomas(1-5)
Temozolomide therapy seems to lead to mismatch repair deficiency and hypermutation in gliomas, but not to an increase in response to immunotherapy.